DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
- Conditions
- Breast CancerNon-small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 115
- Registration Number
- NCT04042701
- Locations
- 🇺🇸
Univ. of Cali. San Francisco Medical Center, San Francisco, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Cancer Specialists of North Florida (Cbo), Jacksonville, Florida, United States
Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
- Conditions
- Baseline Epidemiologic Assessment
- Interventions
- Drug: MorphaBond ERDrug: Comparator Drug
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 17566
- Registration Number
- NCT04033094
- Locations
- 🇺🇸
Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
- Conditions
- Mineralocorticoid Receptor AntagonistHypertension
- Interventions
- Drug: Placebo matching CS-3150
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 55
- Registration Number
- NCT04019652
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
- Conditions
- Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 79
- Registration Number
- NCT04014075
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸USC Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Treatment A - 400 mg FastingDrug: Treatment B - 400 mg FedDrug: Treatment C - 200 mg Fed
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT03901313
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Intrathecal (IT) triple chemotherapy prophylaxis
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT03793478
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib
- Conditions
- Acute Myeloid Leukemia With Gene Mutations
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT03746912
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 557
- Registration Number
- NCT03734029
- Locations
- 🇺🇸
Ironwood Cancer & Research Centers - Chandler II, Chandler, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States
Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers
- Conditions
- Drug Pharmacokinetics in Healthy Volunteers
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT03699774
- Locations
- 🇺🇸
Worldwide Clinical Trials (WCT) Early Phase Services, San Antonio, Texas, United States
Food Effects on Milademetan Pharmacokinetics in Healthy Participants
- Conditions
- Food Effects on Pharmacokinetics
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 18
- Registration Number
- NCT03647202
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States